Clinical Value of Circulating Tumor Cells and Hematological Parameters in 617 Chinese Patients with Colorectal Cancer: Retrospective Analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Jul 28

PMID 37507669

Authors

Yuhao He

Xinxin He

Yubo Zhou

Shanshan Luo

Affiliations

Soon will be listed here.

Abstract

Background: Circulating tumor cells (CTCs) have been a non-invasive technique which allows investigation of tumor characteristics. The purpose of this study was to investigate the relationship between circulating tumor cells and colorectal cancer.

Methods: The clinical data of 617 patients with colorectal cancer from October 2019 to March 2022 were retrospectively collected to analyze the correlation between CTCs and clinicopathologic characteristics.

Results: The CTCs value increased with the progression of Tumor(T) stage,Metastasis(M) stage and Tumor Node Metastasis(TNM) stage (P < 0.05), but not with Node (N) stage (P > 0.05). Binary logistic regression analysis showed that CTCs, CEA, CA125 and CA199 were independent risk factors for CRC metastasis. Compared with CTCs, CEA, CA125 and CA199, the Logistic model had the highest AUC (AUC = 0.778,95%CI: 0.732-0.824), and the specificity and sensitivity were 82.9% and 63.2%, respectively. After operation, chemo-radiotherapy and other treatment for CRC, CTCs and CEA were significantly decreased compared with before treatment (P < 0.05). In addition, Spearman Correlation showed significant correlation between CTCs and IgG (P = 0.000).

Conclusion: CTCs, CEA, CA125 and CA199 were independent risk factors for CRC metastasis.CTCs can be used for the prediction of tumur metastasis, and the evaluation of therapeutic effect.

Citing Articles

Construction of diagnostic models with machine-learning algorithms for colorectal cancer based on clinical laboratory parameters.

Si D, Shu Y, Jiang H, Lin X, Yuan Q, Deng S J Gastrointest Oncol. 2024; 15(5):2145-2156.

PMID: 39554582 PMC: 11565110. DOI: 10.21037/jgo-24-516.

References

Zhong X, Zhang H, Zhu Y, Liang Y, Yuan Z, Li J . Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. Mol Cancer. 2020; 19(1):15. PMC: 6982393. DOI: 10.1186/s12943-020-1141-9. View

Bork U, Grutzmann R, Rahbari N, Scholch S, Distler M, Reissfelder C . Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol. 2014; 20(30):10296-304. PMC: 4130837. DOI: 10.3748/wjg.v20.i30.10296. View

Jiang H, Kang B, Huang X, Yan Y, Wang S, Ye Y . Cancer IgG, a potential prognostic marker, promotes colorectal cancer progression. Chin J Cancer Res. 2019; 31(3):499-510. PMC: 6613500. DOI: 10.21147/j.issn.1000-9604.2019.03.12. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Niu N, Zhang J, Huang T, Sun Y, Chen Z, Yi W . IgG expression in human colorectal cancer and its relationship to cancer cell behaviors. PLoS One. 2012; 7(11):e47362. PMC: 3486799. DOI: 10.1371/journal.pone.0047362. View

Chen W, Xia C, Zheng R, Zhou M, Lin C, Zeng H . Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Glob Health. 2019; 7(2):e257-e269. DOI: 10.1016/S2214-109X(18)30488-1. View

Campos-da-Paz M, Dorea J, Galdino A, Lacava Z, Santos M . Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches. Recent Pat Biotechnol. 2018; 12(4):269-279. DOI: 10.2174/1872208312666180731104244. View

Zhong Y, Ma T, Qiao T, Hu H, Li Z, Luo K . Role of Phenotypes of Circulating Tumor Cells in the Diagnosis and Treatment of Colorectal Cancer. Cancer Manag Res. 2021; 13:7077-7085. PMC: 8439983. DOI: 10.2147/CMAR.S316544. View

Vasseur A, Kiavue N, Bidard F, Pierga J, Cabel L . Clinical utility of circulating tumor cells: an update. Mol Oncol. 2020; 15(6):1647-1666. PMC: 8169442. DOI: 10.1002/1878-0261.12869. View

10.

Bork U, Rahbari N, Scholch S, Reissfelder C, Kahlert C, Buchler M . Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 2015; 112(8):1306-13. PMC: 4402459. DOI: 10.1038/bjc.2015.88. View

11.

E Silva V, Chinen L, Abdallah E, Damascena A, Paludo J, Chojniak R . Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. Onco Targets Ther. 2016; 9:7503-7513. PMC: 5167467. DOI: 10.2147/OTT.S115268. View

12.

Gao Y, Wang J, Zhou Y, Sheng S, Qian S, Huo X . Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Sci Rep. 2018; 8(1):2732. PMC: 5807317. DOI: 10.1038/s41598-018-21048-y. View

13.

Gu Y, Duan B, Sha J, Zhang R, Fan J, Xu X . Serum IgG N-glycans enable early detection and early relapse prediction of colorectal cancer. Int J Cancer. 2022; 152(3):536-547. DOI: 10.1002/ijc.34298. View

14.

Raza A, Khan A, Inchakalody V, Mestiri S, Yoosuf Z, Bedhiafi T . Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer. J Exp Clin Cancer Res. 2022; 41(1):99. PMC: 8922757. DOI: 10.1186/s13046-022-02318-0. View

15.

Hu M, Wang Z, Wu Z, Ding P, Pei R, Wang Q . Circulating tumor cells in colorectal cancer in the era of precision medicine. J Mol Med (Berl). 2021; 100(2):197-213. PMC: 8770420. DOI: 10.1007/s00109-021-02162-3. View

16.

Kdimati S, Mullins C, Linnebacher M . Cancer-Cell-Derived IgG and Its Potential Role in Tumor Development. Int J Mol Sci. 2021; 22(21). PMC: 8583861. DOI: 10.3390/ijms222111597. View

17.

Yadav A, Kumar A, Siddiqui M . Detection of circulating tumour cells in colorectal cancer: Emerging techniques and clinical implications. World J Clin Oncol. 2022; 12(12):1169-1181. PMC: 8716996. DOI: 10.5306/wjco.v12.i12.1169. View